

# Biospecimen Data Is Critical to Realizing Personalized Medicine


Carolyn C. Compton, M.D., Ph.D.

Director, Office of Biorepositories and Biospecimen Research



## **The Personalized Medicine Universe**





# The Demand for High Quality Human Specimens Across the NCI



Identification of targets for drug development, treatment and prevention

Gldentify biologic variations that determine drug efficacy and drug toxicity

Defining markers for susceptibility, screening and reoccurrence

Development of molecular based taxonomy of cancer

Elucidation of molecular mechanisms of neoplasia

Development and validation of new therapeutics

Development and validation of new diagnostics

All Depend
On High-Quality, Annotated
Human Biospecimens



## **OBBR's Strategies: Solutions Built on Informatics**



### Stepwise Approach to Solutions:

- Standards
  - The NCI's Best Practices for Biospecimen Resources
- Science
  - •The Biospecimen Research Network
- Specimens and Service
  - The Cancer Human Biobank

## What Is a Biospecimen Resource?



NCI defines a biospecimen resource as a collection of human specimens and associated data for research purposes, the physical entity where the collection is stored, and all relevant processes and policies.

# NCI's Best Practices for Biospecimen Resources: http://biospecimens.cancer.gov





### National Cancer Institute Best Practices for Biospecimen Resources

June 2007

Prepared by:

National Cancer Institute

National Institutes of Health

U.S. Department of Health and Human Services

- State-of-the-science baseline for operating standards on which to build as the state of the science evolves
- Unifying policies and procedures for biospecimen resources supported by the NCI or used by NCI-supported investigators
- Web version 2009 capabilities:
  - Hyperlinks to outside resources and references
  - Internal links between various sections
  - Search functionality
- First step to improve the quality of human biospecimens used in cancer research
- Update in 2009-10; release to Federal Register this month



### **The NCI Best Practices Overview**



#### **NCI Best Practices include recommendations for:**

- Technical, operational and safety best practices
- Quality assurance and quality control programs
- Implementation of enabling informatics systems
- Addressing ethical, legal, and policy issues
- Establishing reporting mechanisms
- Providing administration and management structure
- Definitions of key terms



## **OBBR's Strategic Plan**




### Stepwise Approach to Solutions:

- Standards
  - The NCI's Best Practices for Biospecimen Resources
- Science and Technology
  - The Biospecimen Research Network
  - The Innovative Molecular Analysis Technologies
- Specimens and Service
  - The Cancer Human Biobank

# **Understanding the Biology of Biospecimens: The Goal of Biospecimen Science**





# Pre-analytical Variables Can Affect Molecular Composition and Integrity



### Variables (examples):

- Antibiotics
- Other drugs
- Type of anesthesia
- Duration of anesthesia
- Arterial clamp time

## Time 0

Variables (examples):

- Time at room temperature
- Temperature of room
- Type of fixative
- Time in fixative
- Rate of freezing
- Size of aliquots



**Patient** 



**Procedures** 



Acquisition



Handling/ Processing



Storage



Distribution



Scientific Analysis



Pre-acquisition

Post-acquisition

# How Can Changes in Molecular Integrity of Biospecimens Affect Molecular Readout?




### Genomics




- Changes in specific transcript levels based on ischemic time, for example, not disease
- Change in RNA levels with frozen storage time or freeze-thaw cycles

### **Proteomics**



- Lack of reproducibility of protein biomarkers in discovery research
- Inconsistent IHC results in research and clinical labs

### **Metabolomics**




Inconsistencies in small molecule readouts, yielding results that point to the wrong pathway





### Ischemia regulated genes c-fos, HIF-alpha and HO-1




## Tissue ischemia and gene expression profiling

(Comparison Affymetrix data and real-time RT-PCR)


Slide Compliments of Dr. Hartmut Juhl, Indivumed GmbH, Hamburg


Sprüssel et al, BioTechniques 2004





## **Intrasurgical Ischemia**






**Indivumed-NCI Study** 





### Tumor marker CEA (colorectal cancer biomarker) and cytokeratin CK20




## Tissue ischemia and gene expression profiling

(Comparison Affymetrix data and real-time RT-PCR)

Slide Compliments of Dr. Hartmut Juhl, Indivumed GmbH, Hamburg


# Phosphoprotein Expression and Postsurgical Ischemia: OBBR Office of Biorepositories pMAPK Immunostaining (Ventana)







- Sponsorship for new research: the BRN extramural research program
- Creation of IT tool to make existing and emerging biospecimen research data more accessible:
  - The Biospecimen Research Database (BRD): searchable web tool
  - Searchable by:
    - Specimen type
    - Variable type
    - Target molecule type
    - Analysis platform type
- Creation of data-driven SOPs for biospecimens used in research




Detail

| Specimen: Tissue / Colorectal / Formalin / Normal


Platform: DNA - DNA Sequencing /

Findings: DNA sequence analysis confirmed SNP results.

E-b








## **OBBR's Strategic Plan**

### Stepwise Approach to Solutions:

- Standards
  - The NCI's Best Practices for Biospecimen Resources
- Science and Technology
  - The Biospecimen Research Network
  - The Innovative Molecular Analysis Technologies
- Specimens and Service
  - The Cancer Human Biobank

# Providing Resources for the Research Community: The Cancer Human Biobank (caHUB)



#### The vision:


- unique, centralized, non-profit public resource
- source of adequate and continuous supplies of human biospecimens and associated data of measurable, high quality acquired within an ethical framework
- source of high-quality biobanking services for the community







- Scientifically designed collection strategies (including rare diseases)
- Multiple aliquots of every specimen
- Standardized, annotated collection, processing of all specimens
- Centralized QC and pathology analysis of every specimen
- Rich, standardized data profile for each sample
- Centralized source of normal human specimens
- Provision of tools, resources, training for U.S. biospecimen resources







- The need for caHUB has been clearly enunciated from all sources:
  - Survey of 5000 trans-NCI investigators (750 respondants)
  - Direct input to OBBR from potential users: CTEP, NCI Patient Characterization Center (PCC), numerous biomarkers programs
  - Mining of request data from the NCI Tissue Locator: last 7 years
  - Market research using focus group sessions with academia and industry decision-makers (OMB-approved; Strat@com-executed)
    - Focus group upcoming for regulators
  - Interviews with commercial tissue providers and industry users (economics considerations study by Booz Allen Hamilton)
  - caHUB Users Workshop

**Programs** 

#### **Centralized Resource: Cost and Quality Control Efficiencies Tumor NCDB Specimens NCI / NIH** National Biospecimen Pathology Reference and Data Biospecimen Access Resource **From Patients** in COC-Other **Approved** Government Institutions caBIG® caHUB **Academia High Quality Specimens High Quality Data** Normal **Specimens** From patients who receive **Advocacy** and Data **High Quality Care From Rapid Autopsy and OPO Consulting Services** Industry

# caHUB Collection Design: Informed by User Need




In high demand and short supply:

- Benchmark samples
  - Collected through standardized methods with strict quality control and metrics
  - Data associated with process variables
- Cases with multiple aliquots
  - Confirmation of prior studies
  - Opportunity to extend prior studies based on new technologies / analyses
- Statistically valid numbers of biospecimen sets
- Fully defined "patient case sets"
  - Tumor
  - Adjacent normal tissue
  - Tumor periphery (invasive border)
  - Pre- and post operative blood samples
  - Urine
  - Rich clinical data and outcome information for patients
- Non-surgical samples: normal tissues; metastases; pre-malignancy


# **Biospecimen Variation Thwarts Innovation in Medical Science**





**Scientific Progress?** 

# Biospecimen Standardization Advances Innovation OBBR Office of Biorepositories in Medical Science: Building on Past Discoveries



## **Informatics Goal for caHUB**



- Establish a comprehensive informatics tools and infrastructure that enables the tracking and sharing of specimens and associated data of many types with the research community.
- Deliverables include:
  - An integrated system that manages the collection and analysis of data related to biobanking and business operations, clinical data, specimen analysis data, and quality management
  - Fully operational informatics portal that provides a central access point that links to all caHUB related databases with the appropriate permissions established for each user group
  - An interface between caHUB and the National Cancer Database (NCDB) that leverages and expands the current NCDB functionality
  - Audits of data quality and information security

## Data Supporting the Business Functions of caHUB

2



#### Infrastructure and Administration

Bioinformatics Core/IT

- Building and Facilities
- Management and Personnel

# Biospecimen Collection and Shipping

Biospecimen Processing Biospecimen Storage Management Biospecimen Retrieval and Distribution

- Tissue Collection
- Preliminary Pathology and Histology Review
- Quality Validation
- Specimen Recording
- Consent Documentation
- Barcode Labeling and Scanning
- Data Collection
- Packaging and Shipping

- Detailed Pathology, Imaging, and Molecular Analysis
- Bioinformatics
   System Data Entry
- Link Assay, Test Results and Annotation to Specimens
- Barcode Labeling and Scanning

- Liquid Nitrogen,
   -80, and room
   Temperature
   Storage
- Inventory Control
- Barcode Scanning
- Freezer Room Monitoring and Physical Security
- Climate Control/ Backup/Alarm Systems
- Periodic Auditing of Inventory

- Specimen Retrieval Equipment
- Barcode Scanning
- Packing and Shipping
- Inventory Reconciliation
- Validation of Customer Receipt
- Customer Sales and Invoicing

5

## The caHUB as a Data Resource for Users



- Data available through the system:
  - Specimen type, amount, diagnosis, pathological characteristics, macroand microscopic appearance
  - Collection, processing, storage, distribution
  - Quality control metrics
  - Clinical information about the patient/donor at multiple time-points
  - Molecular analysis results from different platforms

 The comprehensive data base may, with maturation over time, become more useful to the scientific community that the specimens themselves (in silico research)

## caHUB, A Transformative Initiative



# **8. Biobanks**By ALICE PARK


OBBR Office of Biorepositories and Biospecimen Research



Inside
Huntsman
Cancer
Institute's
vaults:
Pancreatic
tumors on
ice.
Lance W.
Clayton for
TIME

Folks at the National Cancer Institute (NCI) are heading up an effort to establish the U.S.'s first national biobank — a safe house for tissue samples, tumor cells, DNA and, yes, even blood — that would be used for research into new treatments for diseases.... By fall, the group hopes to have mapped out a plan for a national biobank; the recent stimulus showered on the government by the Obama Administration might even accelerate that timetable.

*Time Magazine* March 23, 2009 *Time* Magazine November 25, 2009



# Biospecimen Data Is Critical to Realizing Personalized Medicine

Carolyn C. Compton, M.D., Ph.D.

Director, Office of Biorepositories and Biospecimen Research



FEATURE
Geek Gardening: A Wired
Guide to Domestic
Terraforming

LATEST
Most Dangerous Object in the
Office: Fire Footbag



FERTURES 18.06

# Libraries of Flesh: The Sorry State of Human Tissue Storage

By Steve Silberman May 24, 2010 | 12:00 pm | Wired June 2010



Of all the forms of woe that take root in the human genome, the cancer called Glioblastoma multiforme is one of the most merciless. It can infiltrate the brain's white matter for months before causing any symptoms. By the time memory loss and seizures reveal the presence of an invader, there's often little to do but minimize the patient's suffering. Most who are diagnosed with the disease—people like the late senator Edward Kennedy—are dead within two years.















## Consensus of the Broad Scientific Community:

The lack of high-quality, clinically annotated human specimens has become the limiting factor for translational cancer research.







2010

2009

2008

2007

2006

2005

2004

2003

2002

- NCI Best Practices for Biospecimen Resources updated and expanded
- caHUB RFPs released
- Cancer Human Biobank (based on NBN) planning takes place
- Widespread adoption of NCI BPs throughout NCI extramural biorepositories
- Biospecimen Research Network launched; First projects funded
- FGGs revised and renamed NCI Best Practices for Biospecimen Resources
- Biospecimen Research Network concept approved; First Symposium held
- First-Generation Guidelines for NCI-Supported Biorepositories (FGGs) developed by OBBR and BCC and published in Federal Register
- Office of Biorepositories and Biospecimen Research established
- International Summit on Harmonization of biorepositories conducted
- caBIG<sup>™</sup> software tools for biorepositories developed
- Analysis of NCI-supported biospecimen resources conducted
- Trans-NCI Biorepository Coordinating Committee (BCC) formed
- Case Studies of Existing Human Tissue Repositories published
- National Biospecimen Network (NBN) Blueprint published
- Biospecimen resources identified as critical resources for cancer research



### **NCI Best Practices Revision Process 2009**



- The 2007 NCI Best Practices were revised and updated by the BCC
- Perspectives from multiple OBBR-sponsored workshops included
- Comments from relevant NIH and HHS offices were incorporated
- Public comment on the NCI Best Practices to be sought through a Federal Register notice beginning this month
- The updated BPs will continue to use an online format and will focus on providing additional appendices/resources for detailed information

### 2009 Web-based Format: NCI Best Practices





http://biospecimens.cancer.gov/bestpractices

## **Features of New Interactive Format**



### Additional capabilities include:

- Hyperlinks to outside resources and references
- Internal links between various sections within the NCI Best Practices
- Search functionality of *NCI Best Practices* content

### Interactive features to encourage stakeholder input:

- Feedback form
- Polls
- Sign-up form for updates on the NCI Best Practices





#### Technical and Operational Practices

- New section "Biospecimen Resource Management and Operations"
- Updated references & websites for further information throughout
- Perspectives from OBBR workshop on Biobanking Economics

### Ethical, Legal and Policy Issues

- o Perspectives based on the findings of OBBR-NCI workshops:
  - Custodianship / Ownership
  - o Pediatric Consent
- Revised informed consent, withdrawal of consent and privacy recommendations to reflect current US federal guidance
- New section on "Conflicts of Interest" to coincide with new NIH policy

### New Appendices

- o "Minimal Clinical Data Set"
- Template biospecimen resource "Governance Plan"
- Compilation of resources related to Ethical, Legal and Policy Issues

# **BRN Extramural Research Will Benefit the Entire NCI Community**



- Biospecimen molecular integrity:
  - Effects of blood specimen handling procedures on protein integrity
  - Credentialing plasma and serum biospecimen banks for proteomics
  - Intrinsic and extrinsic controls for FFPE tissue
  - Effects of biospecimen integrity on microarray-based pharmacogenomics tests of breast cancer
- Tissue acquisition process variables and molecular analysis results:
  - Define the procedural variations that cause the most significant variations in molecular composition and integrity
    - Time to fixation
    - Length of fixation
    - Different processing parameters
  - Use this data to inform the development of evidence-based Standard Operating Procedures (SOPs)

# **IMAT: Technology Solutions for Molecular Analysis with Broad Benefit**




### Key features:

- Coordinated through OBBR; managed through the divisions
  - Trans-NCI needs are addressed through centralized approach
- Innovation-focused, early stage technology development
  - High-risk, high-impact
- Cutting-edge ideas through commercialization
- Block-buster incubator:
  - RNAlater®
  - Affymetrix chips
  - Illumina beads
  - MudPit
  - Protein arrays (Micro-proteomic profiling of FFPE)
  - Quantum dots
  - Cold PCR
  - RainDance ®
- Commitment to diversity: CHCRD training/teaching collaboration











**COMMODITIES:** Cost Recovery

Distribution of specimens and data
Increasing value of aliquots over time with increasing data richness:
Time-dependent maturity

SERVICES: Revenue Generation

Build on existing infrastructure and improve return on investment:

Not time-dependent

- Biobanking services to other initiatives
  - Other NCI/NIH
  - > Rare diseases
  - Advocacy
- > Education and training
  - Pathology and laboratory functions
  - Operating room functions
  - > IT and data management
  - Biostatistical and analytic methods

- Consulting services
  - > Biobanking methods and best practices
- Biobanking support service to industry
  - > Assay development
  - Clinical trials
- > Laboratory space and services
  - Research incubator functions
  - > Longer term in-house research contracts





- Provide state-of-the-science guidance and tools for the use of human biospecimens in NCI research of all types
- Sponsor scientific investigation and educational activities that continually improves the scientific strength of all human specimen-related practices
- Sponsor technology development for human specimen-related needs
- Serve as a consultative resource for all biobanking activities across the NCI and the NIH
- Partner with professional organizations that are stakeholders in medical research and personalized medicine; harmonize national/international efforts
  - AACR, FDA, NIST, CAP, ACS, SPIDIA
- Fill the gap of availability of highest quality human biospecimens for research through implementation of standards of care in personalized medicine

# Why Is It Difficult to Acquire High-Quality Specimens and Data?



- Collection, procession, storage procedures differ
- Degree and type of data annotation varies
- Scope and type of patient consent differs
- Access policies are lacking or unknown to potential users
- Materials transfer agreement conditions differ
- Supporting IT structures differ in capacity and functionality
- → WIDE VARIATION IN QUALITY OF SPECIMENS AND DATA